Equity Sample Clauses

Equity. All shares of restricted stock granted to the Executive by the Company shall become vested in full upon the termination. Additionally, if the termination occurs prior to the Performance Share Vesting Date, the vesting of 100% of the Target Number of Performance Shares shall be accelerated and such Performance Shares shall be deemed Vested Performance Shares effective as of the date of the termination. The vesting of all Unvested Common Shares issued in settlement of the Performance Share Award shall be accelerated in full effective as of the date of such termination. Except as set forth in this Section 8(e)(i)(c), the treatment of stock options, performance share awards and all other equity awards granted to the Executive by the Company that remain outstanding immediately prior to the date of such Change in Control shall be determined in accordance with their terms.

Equity. The Company granted the Executive a nonstatutory stock option to purchase 120,000 shares of Company common stock (the “Option”), a performance restricted stock unit award covering 30,000 shares of Company common stock (the “PSU”), and a restricted stock unit award covering 15,000 shares of Company common stock (the “RSU and together with the Option and the PSU,(the “Stock Awards” and the “Grant”) in each case as an Inducement Award and outside of the Company’s 2015 Equity Incentive Plan (the “Plan”). The Grant will be subject to the terms and conditions of the Plan and the applicable stock option grant agreement and restricted stock unit agreement. Subject to Executive’s continued employment through the applicable vesting dates, the Option shall vest over three years with one-third vesting on the one year anniversary of the Commencement Date and the remaining two-thirds vesting in eight equal quarterly installments after the conclusion of each quarter thereafter, subject to accelerated vesting in certain circumstances pursuant to Article 6 below. The PSU shall vest as follows: subject to Executive’s continuous service through such dates, (i) 10,000 shares of Company common stock underlying the PSU shall vest upon the Compensation Committee’s written confirmation that the Company has first achieved net reported revenue of $200 million in a given year (ii) 10,000 shares of Company common stock underlying the PSU shall vest upon the Compensation Committee’s written confirmation that the Company has completed a significant acquisition and (iii) 10,000 shares of Company common stock underlying the PSU shall vest upon the Compensation Committee’s written confirmation that the Company has successful filed a New Drug Application with the U.S. Food & Drug Administration; provided, however, that if any of the preceding events occurs before the one-year anniversary of the Commencement Date, then the portion of the PSU that relates to such event will vest upon such one-year anniversary of the Commencement Date. The RSU shall vest as follows: subject to Executive’s continuous service through such dates, one-third of the shares of Company common stock underlying the RSU shall vest on the one-year anniversary of the Commencement Date and the remaining two-thirds shall vest in equal installments over the following eight quarters, after the conclusion of each quarter, thereafter. Subject to approval by the Company’s Compensation Committee, in consultation with the independ...

Equity. Executive will be eligible to receive awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board (or its compensation committee) will determine in its discretion whether Executive will be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time, provided that in no case will the terms of any such award deviate from the accelerated vesting provisions set forth elsewhere herein.

Equity. The Recipient is to consider Gender Based Analysis Plus (“GBA+”) lenses when undertaking a project.

Equity. Party B will not issue, purchase or redeem any equity or debt securities of Party B.

Equity. The parties agree that any tax issues, or payments that are due to the IRS or comparable foreign entity as a result of issuance of the equity to Executive, are the sole responsibility of Executive. Executive understands that its own obligation to consult with and take his own independent tax advice on this matter. (a) 2022 Incentive Plan (appendix A) The Executive will be eligible to participate in the Company’s 2022 Incentive Plan, as per the Stock Option Grant detail (appendix B.).

Equity. In partial consideration of the license granted to Company under this Agreement, on or about April 18, 2003, Company shall issue to Medical School a total number of shares of Common Stock of Company, ($.01 par value per share) equal to {***} of the outstanding shares of Company. Company shall register the shares that are issued to the Medical School within ninety (90) days after their issuance and those shares will then be unrestricted.

Equity. Vesting acceleration of one hundred percent (100%) of Executive’s outstanding unvested Equity Awards on the date of Executive’s termination. If, however, an outstanding Equity Award is to vest and/or the amount of the Equity Award to vest is to be determined based on the achievement of performance criteria, then the Equity Award will vest as to one hundred percent (100%) of the amount of the Equity Award assuming the performance criteria had been achieved at target levels for the relevant performance period(s).

Equity. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company’s applicable equity incentive plan(s) and the applicable award agreement(s) (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement: (i) in the event that the Executive’s employment is terminated by the Company without Cause or by the Executive for Good Reason, the Company will negotiate in good faith to establish a non-exclusive limited consulting relationship with the Executive for a period of up to one year after the Date of Termination (as defined below), provided that, for the avoidance of doubt, in no event will the Executive be eligible to receive any cash compensation from the Company during such consulting relationship except as set forth in and subject to the terms of Sections 5 or 6 of this Agreement; provided further, that any such consulting relationship shall be subject to a consulting agreement that will contain, among other provisions, the Company’s then current standard general release of claims against the Company and all related persons and entities and, in the Company’s sole discretion, a one year post-employment noncompetition agreement, and shall include a seven (7) business day revocation period; (ii) in the event that the Executive’s employment is terminated by the Company without Cause or by the Executive for Good Reason, in each case, during the Change in Control Period (as defined below), all of the then-outstanding and unvested portion of the Executive’s stock options and other stock-based awards that (A) are subject solely to time-based vesting or (B) were granted to the Executive prior to the Effective Date and are subject to performance-based vesting (the “Performance-Based Awards”) shall become fully vested and exercisable or nonforfeitable immediately as of the Date of Termination or, if later, the Change in Control (as defined below), with any such Performance-Based Awards vesting at target. For the avoidance of doubt, (I) the forfeiture provisions upon a Change in Control described in the Plan (as defined below) shall not apply to the Executive’s equity awards that are subject to acceleration pursuant to this subsection, and (II) any stock options or other stock-based awards that are subject to performance-based vesting and that are granted to the Executive after the Effective Date shall not b...